G3’s Cardiovascular Disease Biomarker and Drug Target Discovery Study (the “GLOBAL” Study) is the Single Largest Prospective Pan-Omic Study to Employ Whole Genome Sequencing
RICHMOND, Va., and SAN DIEGO, Sept. 25, 2013 – Global Genomics Group (G3) and Illumina, Inc. (NASDAQ:ILMN) today announced that they have entered into a partnership to investigate novel biomarkers and biological pathways involved in the development and diagnosis of cardiovascular diseases. Under the terms of the agreement, Illumina will conduct whole genome sequencing (WGS) in the GLOBAL (Genetic LOci and the Burden of Atherosclerotic Lesions) clinical study. GLOBAL is the largest pan-omic study combining genomics, epigenomics, transcriptomics, proteomics, metabolomics, lipidomics, lipoprotein proteomics and glycomics with coronary computed tomographic (CT) angiography, an advanced imaging technology for phenotyping that allows the precise classification of disease in patients.
“The development and progression of conditions such as cardiovascular disease involves poorly understood complex biological processes that require comprehensive investigative approaches to identify new disease biomarkers and therapeutic targets,” said Szilard Voros, M.D., chief executive officer and co-founder of G3. “This is the first study of its kind, analyzing trillions of data points from 7,000 patients, designed to investigate the biological basis behind the complex processes responsible for atherosclerosis. We are applying the most advanced coronary CT angiography techniques to precisely phenotype atherosclerotic disease, while conducting a complete pan-omic analysis in every patient. WGS is a centerpiece of this landmark study, and this collaboration with Illumina and its most advanced next-generation sequencing technology is essential to the success of the program. To date we have collected more than 2,200 samples, and we anticipate completing enrollment by summer of 2014.”
Matt Posard, senior vice president and general manager of Illumina’s Translational and Consumer Genomics business, added, “Consistent with Illumina's strategy of partnering with clinical thought leaders, we are excited to expand our footprint in cardiovascular genomics with G3. The GLOBAL study will be one of the largest patient studies involving genomic sequencing and will be the largest pan-omic WGS study Illumina has participated in to date. The sequencing data will be a critical component in deciphering the complexities of the development and diagnosis of atherosclerosis.”
The ongoing GLOBAL study (ClinicialTrials.gov Identifier NCT01738828) is an international, prospective, multi-center study recruiting up to 7,000 patients to characterize novel disease networks and biomarkers for coronary artery disease (CAD). The study is being funded by G3 and conducted together with strategic partner Health Diagnostic Laboratory. Eligible patients undergo coronary CT angiography providing an accurate and detailed examination of the disease and disease status. This precision phenotyping is combined with a pan-omic analysis, and the data is then analyzed utilizing specifically developed systems biology-based bioinformatics technology for identification of diagnostic biomarkers and potential therapeutic targets.
“The GLOBAL study will involve the collection of 22 trillion data points used to decode the complex biology underlying atherosclerotic disease,” said Tonya Mallory, chief executive officer, president and co-founder of Health Diagnostic Laboratory, a strategic partner of G3. “The study will represent validation of this technology and opens the door to similar analyses of other diseases, such as oncologic, neurodegenerative and psychiatric, with the goal of identifying novel biomarkers and therapeutic targets for diagnosis, prevention and treatment of these serious and debilitating diseases.”
About Global Genomics Group (G3)
G3 is a life sciences company investigating biological networks that lead to the development of disease to identify novel diagnostic biomarkers and therapeutic targets. G3 combines precision phenotyping with pan-omics (genomics, epigenomics, transcriptomics, proteomics, metabolomics, lipidomics, lipoprotein proteomics and glycomics) and bioinformatics to investigate the development and progression of conditions such as atherosclerosis in cardiovascular disease.
For additional information, please visit www.globalgenomicsgroup.com
Illumina is a leading developer, manufacturer, and marketer of life science tools and integrated systems for the analysis of genetic variation and function. We provide innovative sequencing and array-based solutions for genotyping, copy number variation analysis, methylation studies, gene expression profiling, and low-multiplex analysis of DNA, RNA, and protein. We also provide tools and services that are fueling advances in consumer genomics and diagnostics. Our technology and products accelerate genetic analysis research and its application, paving the way for molecular medicine and ultimately transforming healthcare.
This release may contain forward looking statements that involve risks and uncertainties. Important factors that could cause actual results to differ materially from those in any forward-looking statements are detailed in our filings with the Securities and Exchange Commission, including our most recent filings on Forms 10-K and 10-Q, or in information disclosed in public conference calls, the date and time of which are released beforehand. We do not intend to update any forward-looking statements after the date of this release.
Martina Schwarzkopf, Ph.D.
Russo Partners, LLC
12 West 27th Street, 4th Floor
New York, NY 10001
T (212) 845-4292
M (347) 591 8785
F (212) 845-4260